RxDoctor Payments Data

Donald Pallone

Family · Punxsutawney, PANPI 1932384138

Payments from drug & device makers

$762in general payments, 2019–2025

Across 32 payments — averaging $23.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$185
  • Davol Inc.$147
  • Johnson & Johnson$57
  • Amarin Pharma, Inc.$46
  • Novo Nordisk$42
  • AbbVie$39
  • plus $245 from 12 others

What the payments were for

  • Food & beverage$762100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$762 in reported general payments places this provider in the 65th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$23,168
Medicare patients
66
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$86,614
TrulicityDulaglutide17$25,476
JardianceEmpagliflozin22$17,870
FarxigaDapagliflozin Propanediol13$12,295
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/715$8,744
DuleraMometasone/Formoterol13$5,953
Incruse ElliptaUmeclidinium Bromide13$5,336
Albuterol Sulfate HfaAlbuterol Sulfate68$3,158
Venlafaxine Hcl ErVenlafaxine Hcl25$3,032
Atorvastatin Calcium188$2,869
Potassium Chloride98$2,746
Omeprazole173$2,609
Metoprolol Succinate90$2,415
SynthroidLevothyroxine Sodium45$2,359
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$17$25,47617 claims
AstraZenecaFarxiga$185$12,29513 claims
MerckDulera$13$5,95313 claims
GSKIncruse Ellipta$15$5,33613 claims
AbbVieSynthroid$39$2,35945 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,717 family providers in Pennsylvania.

Other family in Punxsutawney

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →